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doi:10.1016/j.thromres.2012.02.040a b s t r a c ta r t i c l e i n f oAvailable online 15 March 2012 Factor XIII is a coagulation factor with multiple plasmatic and cellular functions part of which is outside of the
ﬁeld of traditional hemostasis. The aim of the review is to provide a brief summary on the relationship be-
tween coagulation factor XIII (FXIII) and the cells of the immune system. In the ﬁrst part the structure and
biochemical functions of plasma and cellular FXIII are brieﬂy summarized. Then, the interaction between leu-
kocytes and factor XIII is discussed. This part includes the activation of FXIII by human neutrophil elastase,
the down-regulation of activated FXIII (FXIIIa) by granulocyte proteases within the clot, and the effect of
FXIIIa on leukocytes. In the following part data on the expression and subcellular distribution of FXIII in
monocytes/macrophages are summarized. Another part of the review is devoted to changes of FXIII expres-
sion during monocyte differentiation and monocyte activation by the classical or the alternative pathway. In
the ﬁnal part reports on the possible functions of cellular FXIII in monocytes and macrophages are evaluated.
© 2012 Published by Elsevier Ltd.Introduction
Plasma factor XIII (pFXIII) is a zymogen consisting of two poten-
tially active catalytic A subunits (FXIII-A) and two protective/carrier
B subunits (FXIII-B). FXIII-A is synthesized in cells of bone marrow or-
igin, but it is not clear how FXIII-A is released from the cellular com-
partment. It does not have a signal peptide and there is no proof for
its secretion by non-classical alternative pathways. FXIII-B is synthe-
sized and secreted by hepatocytes in excess to FXIII-A. The two sub-
units form a tight tetrameric complex (FXIII-A2B2) in the plasma;
practically all FXIII-A is in complex, while about 50% of FXIII-B circu-
lates in free form. A cellular dimeric form of FXIII-A (cFXIII) is also
present in the cytoplasm of platelets and monocytes/macrophages
[1,2].
The concerted action of thrombin and Ca2+ is required for the ac-
tivation of pFXIII (Fig. 1). By cleaving the Arg37- Gly38 peptide bond
thrombin removes the activation peptide from the N-terminus of
FXIII-A. Then, in the presence of Ca2+, FXIII-B dissociates and the
remaining FXIII-A dimer assumes an enzymatically active conﬁgura-
tion (FXIIIa). The activation of pFXIII occurs rapidly on the surface of
ﬁbrin, which accelerates the activation process 80-100-folds [1,2].
The activation of cFXIII in the cytoplasm occurs through a non-
proteolytic mechanism and the rise of intracellular Ca2+ concentra-
tion seems sufﬁcient to bring about the active conﬁguration [3–5].edical and Health Science Cen-
ebrecen, Hungary. Tel.: +36
ek).
sevier Ltd.FXIIIa, a transglutaminase (TG), catalyzes an acyl transfer reaction,
resulting in ε(γ-glutamyl)lysyl cross-links between peptide chains
[1,2]. The main hemostatic function of FXIIIa is to cross-link ﬁbrin
chains and covalently attach the main inhibitor of plasmin, α2-plasmin
inhibitor (α2PI), to ﬁbrin. The cross-linking of ﬁbrin considerably en-
hances its stiffness and rigidity and makes it more resistant against
shear stress. α2PI to ﬁbrin cross-linking has the predominant role of
protecting newly formed ﬁbrin from elimination by the ﬁbrinolytic en-
zyme, plasmin [1,6,7]. The importance of these mechanisms is under-
lined by the severe bleeding diathesis of non-substituted FXIII-A
deﬁcient patients [8,9].
Factor XIII-leukocyte interaction
Activation of FXIII by human neutrophil elastase
Polymorphonuclear (PMN) leukocytes represent a rich source of
proteolytic enzymes; they contain human neutrophil elastase (HNE),
cathepsin G and metalloproteinases, which are released upon activa-
tion. In a few early studies it has been demonstrated that HNE and ca-
thepsin G proteolytically degrade FXIII [10–12]. More recently, it was
shown that HNE induced a limited cleavage of pFXIII or cFXIII that
resulted in their activation, followed bymuch slower proteolytic inacti-
vation (Fig. 2) [13]. Val39-Gln40was identiﬁed as the peptide bond that
was cleaved byHNE to activate FXIII. HNE-activated FXIIIwas capable of
cross-linking ﬁbrin γ-, and α-chains.
Since a sufﬁcient amount of thrombin is formed during blood co-
agulation to activate pFXIII, HNE-induced FXIII activation is not likely
to contribute signiﬁcantly to the formation of FXIIIa. However, in the
extravascular compartment the situation could be different. cFXIII
Fig. 1. The main physiological activation mechanisms of plasma and cellular FXIII. During the proteolytic activation of plasma FXIII (FXIII-A2B2) thrombin cleaves off the activation
peptide from the A-subunits (FXIII-A), then, in the presence of Ca2+ the B subunits (FXIII-B) dissociate from the complex and the cleaved dimer (FXIII-A2’) assumes an enzymat-
ically active conﬁguration (FXIII-A2*). The non-proteolytic activation of cellular FXIII (FXIII-A2) occurs in the presence of Ca2+ and involves a slow transformation of the non-
cleaved, inactive FXIII-A dimer into an active conformation (FXIII-A2°). Green and orange cylinders represent β-barrel and β-sandwich domains of FXIII-A, respectively. The central
core domains in FXIII-A are depicted as horseshoes in magenta. The activation peptide is shown as red loop. The elongated bended structure consisting of 10 pearls surrounding
FXIII-A2 corresponds to FXIII-B; the pearls represent individual sushi domains. The ﬁgure was originally published as a part of a complex ﬁgure in reference [1].
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through capillaries could be present in extravascular body ﬂuids and
serve as a substrate for HNE released by activated inﬂammatoryFig. 2. Transient proteolytic activation followed by complete inactivation of plasma FXIII (pF
FXIII activation by HNE was followed by Western blotting (A) and by spectrophotometric
activated FXIII is present. After 5 min of incubation with HNE (+E) a considerable amount
is measured. The amount of activated FXIII is maximal between 10–20 minutes, then it gradu
also shown on the right lanes of the gels. FXIII-A: intact A subunit of FXIII, FXIII-A*: truncate
was originally published in reference [13] and was reproduced by the permission of the puPMN leukocytes. cFXIII derived from alveolar macrophages was
detected in bronchoalveolar lavage ﬂuid (BALF). In children with
chronic bronchoalveolar inﬂammatory diseases, the amount of cFXIIIXIII) and cellular FXIII (cFXIII) by human neutrophil elastase (HNE). The time course of
transglumatinase activity measurements (B). In the absence of HNE (−E) only non-
of truncated FXIII-A appears and at the same time, signiﬁcant transglutaminase activity
ally decreases due to further proteolysis. For comparison FXIII activated by thrombin is
d active form of FXIII-A, E: puriﬁed human neutrophil elastase, T: thrombin. The ﬁgure
blisher (Schattauer GmbH, Stuttgart, Germany).
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patients the level of D-dimer, the ﬁbrinolytic degradation product of
ﬁbrin(ogen) cross-linked by FXIIIa, was also elevated in BALF and
showed a high level of correlation with PMN count. It seems plausible
that during inﬂammation HNE released from activated PMN leuko-
cytes activates FXIII present in the bronchoalveolar lining ﬂuid and
FXIIIa stabilizes ﬁbrin(ogen) deposits, the persistence of which is a
hallmark of many acute and chronic inﬂammatory lung diseases.
Such mechanism might also operate in other body ﬂuids.
Down-regulation of active FXIII by granulocyte proteases within the clot
PMN leukocytes incorporated in the ﬁbrin clot became activated
without any external stimulus and released proteolytic enzymes,
such as HNE, cathepsin G and matrix metalloproteinase-9, which
then degraded FXIIIa and resulted in the parallel loss of transglutami-
nase activity [15]. The proteolytic degradation of FXIIIa by PMN leu-
kocytes was also signiﬁcant in clots made from whole plasma or
from ﬁbrinogen supplemented with α1-antitrypsin (α1AT), the
main inhibitor of PMN proteases. In the presence of α1AT the degra-
dation of FXIIIa by PMN proteases occurred signiﬁcantly faster than
that of cross-linked ﬁbrin, which suggested that proteases released
from PMN leukocytes could effectively be involved in the inactivation
of FXIIIa within the ﬁbrin clot and down-regulate the cross-linking
process. This mechanism could prevent the formation of an over-
cross-linked ﬁbrin clot difﬁcult to eliminate when it is no longer
needed.
The effect of active FXIII on leukocytes
Another aspect of the interaction between leukocytes and FXIII is
the effect of FXIII on these cells. FXIIIa enhanced the proliferation of
peripheral blood monocytes, accelerated their migration and signiﬁ-
cantly inhibited monocyte apoptosis [16]. These changes were related
to the down-regulation of thrombospondin-1 and to the up-regulation
of c-Jun and Egr-1. Another interesting indirect interaction between
FXIII and macrophages concerns the FXIII-dependent generation of
monocyte chemotactic factor during coagulation [17]. It was suggested
that the cross-linking of active complement fragment C5a or C5a des-
Arg to another plasma protein was involved in the formation of the
major monocyte chemotactic factor present in the serum. However no
clear-cut proof has been provided. Most recently it was shown that a
plasma protein with the features of ribosomal protein S19 (RP S19) is
dimerized by FXIIIa on the surface of activated platelets during the clot-
ting process, and converted into a monocyte-selective chemoattractive
factor [18]. Interestingly, RP S19 showed immunological cross-
reactivity with C5a. Such monocyte speciﬁc chemotactic factor(s)
formed during clotting could be involved in recruiting monocytes/in-
ﬂammatory macrophages to the site of injury. FXIII might also affect
PMN leukocytes, since neutrophils from FXIII-treated rats had lower re-
spiratory burst activity [19].
Cellular factor XIII in monocytes and macrophages
Expression of FXIII in monocytes/macrophages and its changes during
cell activation
It has been known for a long time that cFXIII is present in platelets
in huge quantity. 27 years ago when we ﬁrst reported the presence of
FXIII-A in monocytes [20] and peritoneal macrophages [21], the ﬁnd-
ing was received with some skepticism. However, soon similar results
were reported independently [22] and since then over two hundred
articles have been published on this topic. FXIII-A was detected in a
number of monocyte-derived macrophages including macrophages
of serous cavities, alveolar macrophages, tumor associated macro-
phages, histiocytic and dendritic reticulum cells, connective tissuehistiocytes, perivascular dendritic macrophages, dermal dendrocytes
etc. [23,24]. The demonstration of the speciﬁc mRNA in the above
cell types strongly suggests that they synthesize FXIII-A [25–28].
The expression of FXIII-A in monocytes is up-regulated after malig-
nant transformation as observed in acute and chronic myelomonocy-
tic and monocytic leukemias [29].
The possible co-existence of cFXIII with another transglutaminase,
transglutaminase-2 (TG-2; tissue TG), in monocytes/macrophages
was a debated issue. Now it is clear that in resting non-activated
monocytes cFXIII is the major TG. However, during differentiation or
following activation considerable changes occur. A signiﬁcant eleva-
tion of FXIII-A mRNA and protein level was observed during mono-
cyte/macrophage differentiation in cell culture [30,31] and TG-2 also
became up-regulated [32–34]. Induction of in vitro differentiation of
monocytes into antigen presenting dendritic cells resulted in highly
elevated FXIII-A expression [35–37].
Induction of the classical activation pathway by interferon γ or
Mycobacterium bovis vaccine down-regulated FXIII-A mRNA and pro-
tein expression in cultured macrophages. In contrast, activation by IL-
4 through the alternative pathway resulted in highly elevated FXIII-A
mRNA and FXIII-A antigen level [35]. In line with the in vitro investi-
gations FXIII-A was detected in tumor-associated macrophages that
are considered as alternatively activated, but not in macrophages of
tuberculotic granulomas that go through the classical activation path-
way [35]. Usingmicroarray technique, comparison of normal and FXIII-
A-deﬁcient cultured macrophages demonstrated that in alternatively
activated human macrophages cFXIII was involved in the regulation of
gene expression [38]. The most prominent differences concerned pro-
teins involved in immune functions and wound healing.
Intracellular localization of FXIII in monocytes/macrophages
cFXIII in monocytes/macrophages is of cytoplasmic localization.
However, a few studies indicated that in cultured cells it could be
translocated to the surface [26,30,39]. The appearance of FXIII-A in
the culture medium suggested its secretion by dendritic cells [37].
However, dying or dead cells may be the source of cell surface associ-
ated or soluble phase FXIII. Although there is evidence for cFXIII en-
tering the alternative secretory pathway [40], its actual secretion
has not been demonstrated. The involvement of cFXIII secreted or
surface exposed by resident macrophages in the organization and
remodeling of extracellular matrix by cross-linking matrix proteins
is plausible, however, no experimental proof has been provided to
support this hypothesis. Transient translocation of cFXIII to the nuclei
and the incorporation of FXIIIa substrate into nuclear proteins have
also been demonstrated [41]; the function of FXIIIa in the nuclear en-
vironment is not known.
Functions of cellular FXIII in monocytes and macrophages
A few studies have concerned the intracellular function of cFXIII in
monocytes/macrophages. Several lines of experiments suggest that
cFXIII is involved in the mechanism of phagocytosis by monocytes
and macrophages. Monocytes prepared from FXIII deﬁcient patients
showed an impaired capacity of receptor-mediated phagocytosis
[31]. In cultured monocytes the competitive FXIIIa substrate, MDC,
signiﬁcantly inhibited phagocytosis [31]. A human myelomonocytic
cell line (DD cell line), incapable of phagocytosis and expressing
FXIII-A, demonstrated phagocytosis and FXIII-A expression after par-
tial differentiation following phorbol ester treatment [42]. Another
report suggested the involvement of cFXIII in cell locomotion of den-
dritic cells [36]. As both phagocytosis and cell locomotion involve in-
tracellular contractile elements, the interaction of cytoplasmic FXIIIa
with cytoskeletal components seems feasible. Indeed, FXIIIa-induced
cross-linking of cytoskeletal proteins has been demonstrated in acti-
vated platelets [1].
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covalent dimerization of angiotensin receptor 1 (AT1) by non-
proteolytically activated cFXIII in monocytes [5]. This phenomenon
can be elicited by angiotensin II-induced activation of AT1 plus by
ionomycin-induced elevation of intracellular Ca2+ concentration.
Cross-linked AT1 dimers displayed enhanced Gαq/11-stimulated sig-
naling, increased internalization, desensitization and enhanced adhe-
sion of monocytes to endothelial cells. Such mechanism seems to
operate in hypertensive patients and in apoE deﬁcient mice. Follow-
up studies conﬁrming these ﬁndings are awaited.Conclusions
PMN leukocytes release proteolytic enzymes upon activation among
which HNE is able to activate FXIII. Activation of FXIII by HNE in the
extravascular compartment might play a role in the cross-linking of
ﬁbrin(ogen) at the site of inﬂammation and this waymight be involved
in the pathomechanism of inﬂammatory diseases. Within ﬁbrin clot
PMN leukocytes become activated and proteases released by these
cells inactivate FXIIIa. This is the only known mechanism for the
down-regulation of FXIIIa within the clot. This down-regulation is
important in preventing the formation of over-cross-linked ﬁbrin.
Treatment of peripheral blood monocytes by FXIIIa enhances their
proliferation, accelerates their migration and inhibits their apoptosis.
FXIII might also be involved in the production of monocyte speciﬁc che-
motactic factor(s).
cFXIII, the dimer of FXIII-A, is expressed in monocytes/macro-
phages and in a number of related cell types. It is of cytoplasmic local-
ization, but in certain conditions it can be translocated to the cell
surface or to the nucleus. The mechanism and physiological implica-
tions of these translocations have not been revealed. The expression
of cFXIII is signiﬁcantly increased during monocyte/macrophage dif-
ferentiation in cell culture and following malignant transformation.
The effect of monocyte activation on cFXIII expression depends on
the activation pathway. Activation by the classical pathway down-
regulates cFXIII expression, while activation through the alternative
pathway up-regulates it. The intracellular function of cFXIII in mono-
cytes and macrophages is still to be explored. A few data indicate its
involvement in the mechanism of receptor-mediated phagocytosis
and in the locomotion of dendritic cells, perhaps through interaction
with cytoskeletal elements. A single report implicates cFXIII in the co-
valent dimerization of AT1 receptor in activated monocytes that en-
hances monocyte-endothelial cell interaction and might play a role
in the process of atherogenesis.
The data summarized above are interesting pieces of a puzzle with
the potential of initiating new investigations. However, more re-
search is needed to discover still missing important parts and to as-
semble the pieces into a clear picture that could reveal the full
scope of interactions between FXIII and inﬂammatory cells.Conﬂict of interest disclosure
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